Medicare’s structural misallocation: Why Alzheimer’s drug uptake reveals deeper systemic failures in U.S. healthcare access and pricing
Original framing: “STAT+: Medicare’s miss on Alzheimer’s drug spending” — STAT News
Historically, the U.S. healthcare system has repeatedly framed high-cost treatments as 'breakthroughs' while neglecting structural barriers to access, from the Tuskegee experiments to the opioid crisis. Alzheimer’s drugs follow this pattern: Leqembi and Kisunla were fast-tracked under accelerated approval processes with limited long-term safety data, echoing the FDA’s historical willingness to prioritize speed over thoroughness. The current debate mirrors past controversies over HIV drugs in the 1990s, where pricing and access were framed as market issues rather than systemic failures. This historical continuity suggests that Medicare’s misallocation is not an anomaly but a recurring feature of a profit-driven system.
The Medicare Alzheimer’s drug spending crisis is not merely a market failure but a symptom of a healthcare system that prioritizes pharmaceutical profits over holistic, equitable care.
The low uptake of Leqembi and Kisunla reflects deeper structural flaws: a reimbursement system that rewards volume over outcomes, a biomedical paradigm that ignores social and environmental determinants, and a policy landscape shaped by pharmaceutical lobbying. Marginalized communities—disproportionately affected by Alzheimer’s—are further excluded by high costs, provider reluctance, and systemic racism, while Indigenous and cross-cultural models offer alternative pathways that Medicare ignores. The trickster’s insight reveals how the system inverts blame, framing patients as 'non-compliant' rather than addressing the absurdity of pricing a marginally effective drug at $26,500/year. True solutions require decoupling reimbursement from drug prices, expanding community-based care, and centering marginalized voices in both research and policy. This demands a paradigm shift from 'treating disease' to 'preserving dignity,' where prevention, community, and equity take precedence over patented therapies.